Premium
Determination of didanosine in maternal plasma, amniotic fluid, fetal and placental tissues by high‐performance liquid chromatography–tandem mass spectrometry
Author(s) -
Clark T. Nicole,
White Catherine A.,
Bartlett Michael G.
Publication year - 2006
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.651
Subject(s) - chemistry , chromatography , amniotic fluid , liquid chromatography–mass spectrometry , tandem mass spectrometry , mass spectrometry , tandem , fetus , pregnancy , materials science , composite material , genetics , biology
A rapid and efficient high‐performance liquid chromatography (HPLC)‐tandem mass spectrometry method for the determination of didanosine concentrations in maternal rat plasma, amniotic fluid, placental and fetal tissue samples has been developed and validated. Tissue samples were homogenized in optima water and centrifuged. The supernatant was subjected to solid‐phase extraction (SPE) prior to analysis. Plasma and amniotic fluid samples were extracted without pretreatment. An Agilent 1100 Series HPLC coupled with a Micromass Quattro II triple quadrupole mass spectrometer was used for all analyses. Chromatographic resolution was achieved on a Nova‐Pak phenyl analytical column (2.0 × 150 mm, 4 µm particle size) equipped with a Phenomenex Security‐guard phenyl guard cartridge (2.0 × 4.0 mm) using 60% methanol in 10 m m ammonium acetate buffer mobile phase for all matrices at a flow rate of 0.15 mL/min. The method yields retention times of 2.9 min for didanosine and 3.0 min for the internal standard, stavudine. Limits of detection were 1 ng/mL for all matrices. Recoveries were 70% or greater for both compounds in the different matrices. Within‐ and between‐run precision (%RSD) and accuracy (%error) was less than 15% for all matrices. Copyright © 2006 John Wiley & Sons, Ltd.